A New Microfluidic Device to Facilitate Functional Precision Medicine Assays
Albert Manzano-Muñoz1,2, Jose Yeste3, María A Ortega3,4
1Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Methods in Molecular Biology (Clifton, N.J.)
|December 9, 2023
Summary
Functional precision medicine (FPM) improves cancer treatment but requires many cells and staff. A new microfluidic platform optimizes primary cancer cell use and automates FPM assays, overcoming these limitations.
Area of Science:
- Oncology
- Biomedical Engineering
- Microfluidics
Background:
- Functional precision medicine (FPM) offers a promising approach to personalize cancer therapy.
- Current FPM assays face challenges including high cell input requirements and the need for specialized personnel.
- These limitations hinder the widespread clinical adoption of FPM.
Purpose of the Study:
- To develop and present a novel microfluidic platform for performing functional precision medicine assays.
- To address the limitations of existing FPM assays by optimizing resource utilization and simplifying workflows.
- To demonstrate the potential of microfluidics in automating and enhancing FPM processes.
Main Methods:
- Development of a microfluidic device designed for FPM applications.
- Optimization of primary cancer cell handling and assay performance within the microfluidic platform.
- Implementation of automated fluidic controls for simplified assay execution.
Main Results:
- The microfluidic platform successfully performs FPM assays.
- The system demonstrates optimized use of limited primary cancer cell samples.
- Automation via microfluidics significantly simplifies the assay procedure.
Conclusions:
- The novel microfluidic platform effectively overcomes key limitations of traditional FPM assays.
- This technology enhances the efficiency and accessibility of functional precision medicine.
- Microfluidic automation represents a significant advancement for personalized cancer treatment.
